ACAD
Price
$22.12
Change
-$0.09 (-0.41%)
Updated
Jun 27 closing price
Capitalization
3.7B
30 days until earnings call
ACHFF
Price
$1.36
Change
-$0.02 (-1.45%)
Updated
Jun 27 closing price
Capitalization
90.35M
Interact to see
Advertisement

ACAD vs ACHFF

Header iconACAD vs ACHFF Comparison
Open Charts ACAD vs ACHFFBanner chart's image
ACADIA Pharmaceuticals
Price$22.12
Change-$0.09 (-0.41%)
Volume$3M
Capitalization3.7B
Arch Biopartners
Price$1.36
Change-$0.02 (-1.45%)
Volume$14.1K
Capitalization90.35M
ACAD vs ACHFF Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ACHFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. ACHFF commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and ACHFF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ACAD: $22.12 vs. ACHFF: $1.36)
Brand notoriety: ACAD and ACHFF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 134% vs. ACHFF: 120%
Market capitalization -- ACAD: $3.7B vs. ACHFF: $90.35M
ACAD [@Biotechnology] is valued at $3.7B. ACHFF’s [@Biotechnology] market capitalization is $90.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileACHFF’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • ACHFF’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than ACHFF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while ACHFF’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • ACHFF’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ACHFF is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -2.60% price change this week, while ACHFF (@Biotechnology) price change was +7.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.7B) has a higher market cap than ACHFF($90.4M). ACAD YTD gains are higher at: 20.545 vs. ACHFF (0.741). ACAD has higher annual earnings (EBITDA): 102M vs. ACHFF (-2.68M). ACAD has more cash in the bank: 682M vs. ACHFF (10K). ACHFF has less debt than ACAD: ACHFF (2.38M) vs ACAD (56M). ACAD has higher revenues than ACHFF: ACAD (996M) vs ACHFF (0).
ACADACHFFACAD / ACHFF
Capitalization3.7B90.4M4,095%
EBITDA102M-2.68M-3,806%
Gain YTD20.5450.7412,774%
P/E Ratio16.15N/A-
Revenue996M0-
Total Cash682M10K6,820,000%
Total Debt56M2.38M2,351%
FUNDAMENTALS RATINGS
ACAD vs ACHFF: Fundamental Ratings
ACAD
ACHFF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
26100
PRICE GROWTH RATING
1..100
4248
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5028

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as ACHFF (86) in the null industry. This means that ACAD’s stock grew similarly to ACHFF’s over the last 12 months.

ACHFF's Profit vs Risk Rating (86) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that ACHFF’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for ACHFF (100) in the null industry. This means that ACAD’s stock grew significantly faster than ACHFF’s over the last 12 months.

ACAD's Price Growth Rating (42) in the Biotechnology industry is in the same range as ACHFF (48) in the null industry. This means that ACAD’s stock grew similarly to ACHFF’s over the last 12 months.

ACHFF's P/E Growth Rating (98) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that ACHFF’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADACHFF
RSI
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
66%
Bearish Trend 4 days ago
72%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
61%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
59%
Advances
ODDS (%)
Bullish Trend 13 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
72%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
63%
Aroon
ODDS (%)
Bullish Trend 4 days ago
65%
Bullish Trend 4 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ACHFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MAGCX28.770.16
+0.56%
BlackRock Advantage Global Institutional
ARIBX14.890.04
+0.27%
Aristotle Small Cap Eq I
VWYKX40.910.08
+0.20%
Voya Small Cap Growth W
HQIFX20.700.03
+0.15%
Hartford Equity Income F
CMRCX10.10-0.01
-0.10%
Calamos Merger Arbitrage C

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with INZY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-0.41%
INZY - ACAD
50%
Loosely correlated
-0.25%
AURA - ACAD
45%
Loosely correlated
-0.16%
CRSP - ACAD
43%
Loosely correlated
N/A
PGEN - ACAD
40%
Loosely correlated
-1.40%
PRME - ACAD
40%
Loosely correlated
-8.68%
More

ACHFF and

Correlation & Price change

A.I.dvisor tells us that ACHFF and CCCC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACHFF and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACHFF
1D Price
Change %
ACHFF100%
-1.45%
CCCC - ACHFF
24%
Poorly correlated
-7.89%
AVTX - ACHFF
23%
Poorly correlated
+0.42%
ACAD - ACHFF
23%
Poorly correlated
-0.41%
ALDX - ACHFF
23%
Poorly correlated
-2.07%
EDSA - ACHFF
22%
Poorly correlated
+5.03%
More